Potentiation of Drug Toxicity through Virus Latency Reversal Promotes Preferential Elimination of HIV Infected Cells. Issue 11 (2nd September 2022)

• Record Type: Journal Article
• Authors: Truong, Thanh Tung; Hayn, Manuel; Frich, Camilla Kaas; Olari, Lia‐Raluca; Ladefoged, Lucy Kate; Olesen, Morten T. Jarlstad; Jakobsen, Josefine H.; Lunabjerg‐Vestergaard, Cherie K.; Schiøtt, Birgit; Münch, Jan; Zelikin, Alexander N.
• Is Part Of: Advanced therapeutics. Volume 5:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-02
• Subjects: drug design -- HIV latency -- latency reversal; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.202200113
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Eliminating latently infected cells is a highly challenging, indispensable step toward the cure for HIV/AIDS. Hypothesis put forward herein is that the unique HIV protease cut site (Phe‐Pro) can be reconstructed using a potent inhibitor of tubulin polymerization, monomethyl auristatin F (MMAF), which features Phe at its C‐terminus. This presents opportunities to design prodrugs that are specifically activated by the HIV protease. To this end, a series of MMAF derivatives is synthesized and evaluated in cell culture using latently HIV‐infected cells. The cytotoxicity of compounds is indeed enhanced upon latency reversal by up to 11‐fold. As a result, in a mixed cell population, nanomolar concentrations of the lead compounds depletes predominantly the HIV‐infected cells and in doing so markedly enriches the pool of the uninfected cells. Affinity of the lead compounds to the viral protease is validated computationally and experimentally but despite expectations, the mechanism of action of the synthesized toxins is shown to be independent from the enzymatic activity of the HIV protease. Abstract : Medicinal agents toward the elimination of HIV infected cells via the "shock and kill" strategy are designed. Lead compound exhibits an 11‐fold higher toxicity in cells upon HIV latency reversal. Dosed in vitro at nanomolar concentrations, the lead compound preferentially eliminates the virus‐positive cells and significantly enriches the pool of cells with the virus‐negative cells.